EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
260M of 248M shares
Institutional holders
756
131 new, 64 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
1 buys · 32 sales
Net sold $41.06M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 28,499,470 | 10.20% | 13G (passive) amendment | Mar 31, 2025 |
| Seybold, William | 23,439,500 | 8.40% | 13D (active) amendment | Mar 5, 2025 |
| Wehrly, Mark C. | 18,635,500 | 6.80% | 13D (active) amendment | May 16, 2025 |
| Gehani, Varun N. | 15,709,500 | 5.90% | 13D (active) amendment | Jan 1, 2026 |
| Renaissance Technologies Holdings Corporation | 15,615,716 | 5.16% | 13G (passive) | Dec 19, 2023 |
| Roberts, Jr., Thomas G. | 13,989,010 | 5.60% | 13D (active) amendment | Aug 14, 2026 |
| AQR Capital Management Holdings, LLC | 13,658,388 | 5.09% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 13,233,247 | 5.09% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EXEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 29,075,377 | 11.73% | $1.58B | −1,740,932 | 0.02% |
| Farallon Capital Management LLC | 13,468,010 | 5.44% | $732.79M | +357,000 | 3.38% |
| Renaissance Technologies LLC | 13,427,993 | 5.42% | $730.62M | −299,000 | 1.01% |
| Vanguard Portfolio Management LLC | 12,043,122 | 4.86% | $655.27M | −42,151 | 0.03% |
| Aqr Capital Management LLC | 11,023,943 | 4.45% | $598.60M | −2,071,798 | 0.21% |
| Vanguard Capital Management LLC | 10,950,997 | 4.42% | $595.84M | −307,987 | 0.01% |
| State Street Corp | 9,970,071 | 4.02% | $542.47M | −328,368 | 0.02% |
| Fuller & Thaler Asset Management, Inc. | 8,929,389 | 3.60% | $485.85M | +387,153 | 1.32% |
| Lsv Asset Management | 8,146,478 | 3.29% | $443.25K | +400,763 | 0.80% |
| Geode Capital Management, LLC | 7,650,316 | 3.09% | $416.32M | −145,294 | 0.02% |
| D. E. Shaw & Co., Inc. | 5,551,747 | 2.24% | $302.07M | +1,948,684 | 0.14% |
| Morgan Stanley | 4,519,684 | 1.82% | $245.92M | +341,448 | 0.01% |
| Invesco Ltd. | 4,495,697 | 1.81% | $244.61M | +181,316 | 0.02% |
| Dimensional Fund Advisors LP | 4,426,620 | 1.79% | $240.85M | +127,023 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 4,365,926 | 1.76% | $237.55M | −468,699 | 0.11% |
| Two Sigma Investments, LP | 4,209,861 | 1.70% | $229.06M | +2,003,649 | 0.17% |
| Assetmark, Inc | 3,433,824 | 1.39% | $186.83M | +44,904 | 0.32% |
| Nuveen, LLC | 3,276,984 | 1.32% | $178.30M | −505,750 | 0.04% |
| UBS Group AG | 3,167,890 | 1.28% | $172.36M | +774,377 | 0.02% |
| Stephens Investment Management Group LLC | 2,710,011 | 1.09% | $147.45M | +185,511 | 1.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 756 | 260M | 100.0% | 131 / 257 | 282 / 64 | 23M | 21M |
| Q1 2026 | 701 | 259M | 100.0% | 104 / 246 | 266 / 78 | 46M | 29M |
| Q4 2025 | 685 | 268M | 100.0% | 132 / 234 | 241 / 59 | 36M | 19M |
| Q3 2025 | 621 | 252M | 100.0% | 82 / 224 | 239 / 89 | 24M | 29M |
| Q2 2025 | 635 | 257M | 100.0% | 125 / 234 | 215 / 42 | 28M | 25M |
| Q1 2025 | 558 | 254M | 100.0% | 100 / 216 | 173 / 55 | 27M | 19M |
| Q4 2024 | 519 | 251M | 100.0% | 117 / 175 | 167 / 45 | 25M | 25M |
| Q3 2024 | 454 | 253M | 100.0% | 82 / 144 | 162 / 41 | 54M | 16M |
| Q2 2024 | 416 | 249M | 100.0% | 42 / 142 | 173 / 43 | 12M | 32M |
| Q1 2024 | 422 | 269M | 100.0% | 55 / 136 | 166 / 59 | 21M | 24M |
| Q4 2023 | 427 | 272M | 100.0% | 74 / 137 | 156 / 39 | 29M | 21M |
| Q3 2023 | 399 | 264M | 100.0% | 52 / 134 | 151 / 28 | 18M | 25M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EXEL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 8,601,933 | 3.47% | $468.03M | 0.38% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 7,583,078 | 3.06% | $412.60M | 0.02% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 7,041,516 | 2.84% | $383.13M | 3.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 5,473,447 | 2.21% | $297.81M | 0.16% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 3,156,071 | 1.27% | $171.72M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,881,831 | 1.16% | $156.80M | 0.16% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 2,773,550 | 1.12% | $147.08M | 2.70% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,893,798 | 0.76% | $103.04M | 0.96% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,726,035 | 0.70% | $93.91M | 1.03% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,714,400 | 0.69% | $93.28M | 3.32% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,506,131 | 0.61% | $79.87M | 0.36% | Jul 31, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 1,503,757 | 0.61% | $81.82M | 0.72% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,336,929 | 0.54% | $67.49M | 0.16% | May 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 1,274,068 | 0.51% | $64.31M | 0.06% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF | 1,272,309 | 0.51% | $69.23M | 0.38% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Morrissey | President and CEO, Director | 3,384,063 | 1.37% | May 19, 2026 |
| Dana Aftab | EVP, Research and Development | 600,576 | 0.24% | May 28, 2026 |
| Patrick J. Haley | EVP, Commercial | 357,638 | 0.14% | May 22, 2026 |
| Brenda Hefti | SVP and General Counsel | 112,289 | 0.05% | May 19, 2026 |
| Christopher J. Senner | EVP and CFO | 955,040 | 0.39% | May 19, 2026 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 538,169 | 0.22% | May 16, 2025 |
| Jeffrey Hessekiel | EVP & General Counsel | 694,395 | 0.28% | May 16, 2025 |
| Mary C. Beckerle | Director | 16,079 | 0.01% | Aug 12, 2026 |
| Sue Gail Eckhardt | Director | 16,079 | 0.01% | Jun 3, 2026 |
| Jack L. Wyszomierski | Director | 284,384 | 0.11% | Jun 3, 2026 |
| Julie Smith | Director | 28,957 | 0.01% | May 29, 2026 |
| George Poste | Director | 127,199 | 0.05% | May 29, 2026 |
| Stelios Papadopoulos | Director | 1,197,595 | 0.48% | May 29, 2026 |
| Maria C. Freire | Director | 109,186 | 0.04% | May 29, 2026 |
| Tomas J. Heyman | Director | 50,649 | 0.02% | May 29, 2026 |
| David Edward Johnson | Director | 1,543,906 | 0.62% | May 29, 2026 |
| Partners LP Caligan | Director | 1,571,438 | 0.63% | May 29, 2026 |
| Bob Oliver | Director | 29,487 | 0.01% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mary C. Beckerle Director | Aug 10, 2026 | Sale(10b5-1 plan) | −9,812 | $53.66 | $526.51K | 16,079 |
| Jack L. Wyszomierski Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,925 | $50.55 | $198.41K | 284,384 |
| Sue Gail Eckhardt Director | Jun 1, 2026 | Sale(10b5-1 plan) | −9,812 | $50.14 | $491.97K | 16,079 |
| Mary C. Beckerle Director | May 27, 2026 | Award | +8,367 | – | – | 25,891 |
| George Poste Director | May 27, 2026 | Award | +8,367 | – | – | 127,199 |
| Bob Oliver Director | May 27, 2026 | Award | +8,367 | – | – | 29,487 |
| Stelios Papadopoulos Director | May 27, 2026 | Award | +8,367 | – | – | 1,197,595 |
| Julie Smith Director | May 27, 2026 | Award | +8,367 | – | – | 28,957 |
| Tomas J. Heyman Director | May 27, 2026 | Award | +8,367 | – | – | 50,649 |
| Maria C. Freire Director | May 27, 2026 | Award | +8,367 | – | – | 109,186 |
| Jack L. Wyszomierski Director | May 27, 2026 | Award | +8,367 | – | – | 288,309 |
| Sue Gail Eckhardt Director | May 27, 2026 | Award | +8,367 | – | – | 25,891 |
| Dana Aftab EVP, Research and Development | May 26, 2026 | Sale | −43,451 | $50.35 | $2.19M | 594,741 |
| Patrick J. Haley EVP, Commercial | May 20, 2026 | Sale | −32,110 | $49.81 | $1.60M | 357,638 |
| Michael Morrissey President and CEO, Director | May 18, 2026 | Gift | +124,047 | – | – | 2,004,327 |
| Michael Morrissey President and CEO, Director | May 18, 2026 | Gift | −124,047 | – | – | 1,362,008 |
| Brenda Hefti SVP and General Counsel | May 18, 2026 | Sale(10b5-1 plan) | −6,625 | $50.21 | $332.64K | 106,762 |
| Christopher J. Senner EVP and CFO | May 18, 2026 | Sale | −34,901 | $50.00 | $1.75M | 952,317 |
| Michael Morrissey President and CEO, Director | May 15, 2026 | Tax withholding | −128,497 | $51.10 | $6.57M | 1,486,055 |
| Patrick J. Haley EVP, Commercial | May 15, 2026 | Tax withholding | −33,265 | $51.10 | $1.70M | 389,748 |
| Dana Aftab EVP, Research and Development | May 15, 2026 | Tax withholding | −30,578 | $51.10 | $1.56M | 638,192 |
| Brenda Hefti SVP and General Counsel | May 15, 2026 | Tax withholding | −6,411 | $51.10 | $327.60K | 113,387 |
| Christopher J. Senner EVP and CFO | May 15, 2026 | Tax withholding | −40,892 | $51.10 | $2.09M | 987,218 |
| George Poste Director | May 7, 2026 | Sale | −60,000 | $45.71 | $2.74M | 118,832 |
| Maria C. Freire Director | May 7, 2026 | Option exercise | +20,634 | $19.77 | $407.93K | 121,453 |
| Maria C. Freire Director | May 7, 2026 | Sale | −20,634 | $46.00 | $949.16K | 100,819 |
| Mary C. Beckerle Director | May 7, 2026 | Option exercise | +3,856 | $23.24 | $89.61K | 25,236 |
| Mary C. Beckerle Director | May 7, 2026 | Sale | −7,712 | $48.45 | $373.65K | 17,524 |
| Michael Morrissey President and CEO, Director | May 6, 2026 | Gift | −109,676 | – | – | 1,880,280 |
| Christopher J. Senner EVP and CFO | Feb 26, 2026 | Award | +52,018 | – | – | 1,028,110 |
| Patrick J. Haley EVP, Commercial | Feb 26, 2026 | Award | +40,459 | – | – | 422,367 |
| Dana Aftab EVP, Research and Development | Feb 26, 2026 | Award | +52,018 | – | – | 668,124 |
| Michael Morrissey President and CEO, Director | Feb 26, 2026 | Award | +160,437 | – | – | 1,614,552 |
| Brenda Hefti SVP and General Counsel | Feb 26, 2026 | Award | +23,119 | – | – | 119,631 |
| Michael Morrissey President and CEO, Director | Feb 24, 2026 | Gift | −100,278 | – | – | 1,989,956 |
| Dana Aftab EVP, Research and Development | Feb 24, 2026 | Sale | −47,918 | $44.50 | $2.13M | 616,106 |
| Dana Aftab EVP, Research and Development | Feb 19, 2026 | Sale | −29,873 | $44.35 | $1.32M | 664,024 |
| Jack L. Wyszomierski Director | Feb 18, 2026 | Sale(10b5-1 plan) | −99,574 | $44.01 | $4.38M | 279,942 |
| Jack L. Wyszomierski Director | Feb 18, 2026 | Option exercise | +20,634 | $19.77 | $407.93K | 379,516 |
| Julie Smith Director | Feb 18, 2026 | Sale | −20,030 | $44.30 | $887.33K | 20,590 |
| Julie Smith Director | Feb 18, 2026 | Option exercise | +44,087 | $19.39 | $854.85K | 64,677 |
| Julie Smith Director | Feb 18, 2026 | Sale | −44,087 | $44.50 | $1.96M | 20,590 |
| Julie Smith Director | Feb 18, 2026 | Option exercise | +20,030 | $21.69 | $434.45K | 40,620 |
| Brenda Hefti SVP and General Counsel | Feb 18, 2026 | Sale(10b5-1 plan) | −18,669 | $44.01 | $821.62K | 96,512 |
| Michael Morrissey President and CEO, Director | Feb 18, 2026 | Gift | +125,094 | – | – | 2,090,234 |
| Michael Morrissey President and CEO, Director | Feb 18, 2026 | Gift | −125,094 | – | – | 1,454,115 |
| Julie Smith Director | Feb 17, 2026 | Option exercise | +42,422 | $18.19 | $771.66K | 63,012 |
| Julie Smith Director | Feb 17, 2026 | Sale | −42,422 | $43.33 | $1.84M | 20,590 |
| Michael Morrissey President and CEO, Director | Feb 17, 2026 | Gift | +250,736 | – | – | 1,965,140 |
| Michael Morrissey President and CEO, Director | Feb 17, 2026 | Gift | −250,736 | – | – | 1,579,209 |
| Patrick J. Haley EVP, Commercial | Feb 17, 2026 | Sale | −64,778 | $43.50 | $2.82M | 381,908 |
| Patrick J. Haley EVP, Commercial | Feb 17, 2026 | Sale | −3,036 | $43.84 | $133.10K | 446,686 |
| Christopher J. Senner EVP and CFO | Feb 17, 2026 | Sale | −30,617 | $43.67 | $1.34M | 976,092 |
| Brenda Hefti SVP and General Counsel | Feb 15, 2026 | Tax withholding | −5,430 | $43.92 | $238.49K | 115,181 |
| Dana Aftab EVP, Research and Development | Feb 15, 2026 | Tax withholding | −26,485 | $43.92 | $1.16M | 706,617 |
| Dana Aftab EVP, Research and Development | Feb 15, 2026 | Tax withholding | −12,720 | $43.92 | $558.66K | 693,897 |
| Michael Morrissey President and CEO, Director | Feb 15, 2026 | Tax withholding | −120,390 | $43.92 | $5.29M | 1,829,945 |
| Patrick J. Haley EVP, Commercial | Feb 15, 2026 | Tax withholding | −31,483 | $43.92 | $1.38M | 449,722 |
| Christopher J. Senner EVP and CFO | Feb 15, 2026 | Tax withholding | −35,870 | $43.92 | $1.58M | 1,006,709 |
| Michael Morrissey President and CEO, Director | Feb 13, 2026 | Option exercise | +494,700 | $21.31 | $10.54M | 2,319,941 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Beckerle Mary Director | Aug 10, 2026 | 9,812 | $526.50K | Aug 10, 2026 | Restricted Stock |
| Sue Gail Eckhardt Director | Jun 1, 2026 | 9,812 | $499.14K | Jun 1, 2026 | Restricted Stock Unit |
| L. Wyszomierski Jack Director | Jun 1, 2026 | 3,925 | $198.41K | Jun 1, 2026 | Restricted Stock |
| T. Aftab Dana Officer | May 26, 2026 | 43,451 | $2.19M | May 26, 2026 | Restricted stock vesting under a registered plan |
| Joseph Haley Patrick Officer | May 20, 2026 | 32,110 | $1.60M | May 20, 2026 | Restricted stock vesting under a registered plan |
| Joy Hefti Brenda Officer | May 18, 2026 | 6,625 | $332.64K | May 18, 2026 | Restricted Stock |
| J. Senner Christopher Officer | May 18, 2026 | 34,901 | $1.75M | May 18, 2026 | Restricted stock vesting under a registered plan |
| Rise Foundation Bombora Family foundation of the CEO of EXEL. | May 14, 2026 | 100,000 | $5.09M | May 14, 2026 | Gift from Affiliate |
| C. Freire Maria Director | May 7, 2026 | 20,634 | $949.16K | May 7, 2026 | Exercise of options under a registered plan |
| H. Poste George Director | May 7, 2026 | 60,000 | $2.74M | May 7, 2026 | Restricted stock vesting under a registered plan |
| Beckerle Mary Director | May 7, 2026 | 7,712 | $373.65K | May 7, 2026 | Restricted stock vesting under a registered plan |
| T. Aftab Dana Officer | Feb 24, 2026 | 47,918 | $2.13M | Feb 24, 2026 | Performance Shares |
| T. Aftab Dana Officer | Feb 19, 2026 | 29,873 | $1.32M | Feb 19, 2026 | Performance Shares |
| L. Wyszomierski Jack Director | Feb 18, 2026 | 99,574 | $4.38M | Feb 18, 2026 | Exercised Shares |
| Joy Hefti Brenda Officer | Feb 18, 2026 | 18,669 | $821.66K | Feb 18, 2026 | Performance Shares |